FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD)

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access